ClinicalTrials.gg
CompletedNCT04881994Updated Jul 16, 2021

A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution

A Phase 1 interventional study of Finerenone (BAY94-8862) in Worsening Chronic Heart Failure and Diabetic Nephropathy, sponsored by Bayer. Completed at 1 site in Germany. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-16.

Sponsored by Bayer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 7 years 1 month after the study started (first participant enrolled Mar 2014, registered May 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing finerenone in Diabetic Nephropathies — 5 open to participants now, 5 under way, 1 of them phase 3. finerenone · Diabetic Nephropathies.

Enrollment
10th of 10
27 · median 108
Started
2014
the only one that year
Phase 1
Only one
of the 10
Registered
5th of 10
by date
Lead sponsor
5 of 10
Bayer

Among the 10 studies testing finerenone in Diabetic Nephropathies, this one is the 10th largest by enrollment, is the only one that started in 2014, is the only one in phase 1, and was the 5th registered.

Diabetic Nephropathies

543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

5 of the 10 studies testing finerenone in Diabetic Nephropathies are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing finerenone in Diabetic Nephropathies, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should, as well as to treat patients who have diabetic nephropathy, a long-term, progressive decrease in the kidneys' ability to work properly in patients with diabetes mellitus.

In this study researchers wanted to learn more about a new substance called finerenone (BAY94-8862). Finerenone is a substance that blocks the activation of a protein in the body called mineralocorticoid receptor (MR). An increased activation of MR is involved in the development of hypertension, organ damage and worsening of heart failure.

The researchers studied how finerenone moves into, through and out of the body. The researchers also looked at how safe finerenone is and how it affects the body. The main purpose of this study was to help researchers develop recommendations for the amount of the substance (the dosing) to be given to patients with reduced liver function.

03

Conditions studied

  • Worsening Chronic Heart Failure
  • Diabetic Nephropathy

Keywords

  • Child Pugh A
  • Child Pugh B
  • Liver impairment
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All participants

  • The must be signed before any study specific tests or procedures are done;
  • Male and female white participants;
  • Women of can only be included in the study if a pregnancy test is negative. Women of childbearing potential must agree to use adequate when sexually active. 'Adequate contraception' is defined as any combination of at least 2 effective methods of birth control, of which at least one is a physical barrier (e.g. condoms with hormonal contraception or implants or combined oral contraceptives, certain intrauterine devices). This applies from signing the informed consent form until follow up visit.
  • (BMI): 18 to 34 kg/m2 (both inclusive);
  • Age: 18 to 79 years (both inclusive) at the screening visit;
  • Men must agree to use adequate contraception when being sexually active. This applies from signing of the informed consent until 12 weeks after the last study drug administration. 'Adequate contraception' is defined as any combination of at least 2 effective methods of birth control, of which at least one is a physical barrier (e.g. condoms with hormonal contraception or implants or combined oral contraceptives, certain intrauterine devices);
  • Ability to understand and follow study-related instructions.

Participants with hepatic impairment

  • Participants with documented liver cirrhosis confirmed by histopathology, e.g., previous liver , laparoscopy, ultrasound, or fibroscan;
  • Participants with hepatic impairment ( A or B);
  • Participants with stable liver disease in the last 2 months.

Healthy participants

  • Healthy male and female white participants;
  • Mean age and body weight in the control group and in the two groups with hepatic impairment (Child Pugh A and B) should not vary by more than +/-10 years and +/-10 kg;
  • Gender matched.

Exclusion criteria

Exclusion Criteria:

All participants

  • Participants with a medical disorder, condition, or history of such that would impair the participant's ability to participate or complete this study in the opinion of the investigator or the sponsor;
  • Medical history of Kock pouch (ileostomy after proctocolectomy);
  • Febrile illness within 1 week prior to admission to study center;
  • Relevant diseases within the last 4 weeks prior to admission;
  • Known severe allergies, non-allergic drug reactions, or multiple drug allergies;
  • Known to the study drugs;
  • Participants with diagnosed within the past 5 years;
  • Participants with psychiatric disorders which may disable the participants to consent;
  • Use of the following co-medications from 2 weeks before until 4 days after study drug administration:

    • inducers (e.g. St. John´s wort, rifampicin, carbamazepin, phenytoin, phenobarbital, bosentan, efavirenz, etravirine, nevirapine)
    • weak to moderate CYP3A4 inhibitors (e.g. grapefruit juice and other grapefruit containing products, erythromycin, saquinavir, amiodarone, verapamil, fluconazole, diltiazem)
    • strong inhibitors of CYP3A4 (e.g. itraconazole, ketoconazol, posaconazole, voriconazole, atazanavir, ritonavir, nelfinavir or other inhibitors of (HIV) protease, clarithromycin, telithromycin, nefazodon, telaprevir, boceprevir) or
    • gemfibrozil (a strong inhibitor of CYP2C8)
  • Positive urine drug screening;
  • For women of : positive pregnancy test;
  • Positive results for human immunodeficiency virus 1 and 2 antibodies (HIV-Ag/Ab).

Participants with hepatic impairment

  • Severe cerebrovascular or cardiac disorders, e.g., myocardial infarction less than 6 months prior to dosing, congestive heart failure of grade III or IV, severe arrhythmia requiring antiarrhythmic treatment;
  • Evidence of hepatic encephalopathy related to chronic liver disease >grade 2 (exclusion by Number Connection Test (NCT);
  • Participants with percutaneous transluminal coronary angioplasty or coronary artery bypass graft less than 6 months prior to study drug administration;
  • History of bleeding within the past 3 months;
  • Thrombotic disorder;
  • Participants with diabetes mellitus with a glycohemoglobin A1c () >10%;
  • Severe ascites of more than 6 L (estimated by ultrasound);
  • Participants with primary and secondary biliary cirrhosis;
  • Participants with sclerosing cholangitis;
  • Failure of any other major organ system other than the liver;
  • Severe infection, malignancy, or psychosis, or any illness within 4 weeks prior to study drug administration.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Mild hepatic impairment (Child Pugh A)

    Participants with mild hepatic impairment (Child Pugh A) received single oral dose of finerenone.

    Drug: Finerenone (BAY94-8862)

  • Experimental
    Moderate hepatic impairment (Child Pugh B)

    Participants with moderate hepatic impairment (Child Pugh B) received single oral dose of finerenone.

    Drug: Finerenone (BAY94-8862)

  • Experimental
    Healthy participants

    Healthy age-, weight-, and gender- matched participants received single oral dose of finerenone.

    Drug: Finerenone (BAY94-8862)

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration versus time curve from zero to infinity (AUC) of finerenone in plasma

    Time frame: 0 hour pre-dose to 96 hour post-dose

  2. Area under the concentration versus time curve from zero to infinity of unbound finerenone (AUCu) in plasma

    Time frame: 0 hour pre-dose to 96 hour post-dose

  3. Maximum observed drug concentration (Cmax) of finerenone in plasma

    Time frame: 0 hour pre-dose to 96 hour post-dose

  4. Maximum observed drug concentration of unbound finerenone (Cmax,u) in plasma

    Time frame: 0 hour pre-dose to 96 hour post-dose

Secondary outcomes

  1. Number of participants with adverse events

    Time frame: From the start of study treatment up to 3 days after study treatment

Other outcomes

  1. Percentage of fraction of free (unbound) (fu) finerenone in plasma

    Time frame: 1 hour post-dose

  2. Area under the concentration versus time curve from zero to infinity divided by dose per kilogram body weight (AUCnorm) of finerenone in plasma

    Time frame: 0 hour pre-dose to 96 hour post-dose

  3. Maximum observed drug concentration divided by dose per kilogram body weight (Cmax,norm) of finerenone in plasma

    Time frame: 0 hour pre-dose to 96 hour post-dose

  4. Time to reach maximum concentration (tmax) of finerenone

    Time frame: 0 hour pre-dose to 96 hour post-dose

  5. Half-life associated with the terminal slope (t1/2) of finerenone

    Time frame: 0 hour pre-dose to 96 hour post-dose

07

Study locations

1 site
  • Kiel, Schleswig-Holstein 24105, Germany
08

References and documents

Publications

  • Heinig R, Lambelet M, Nagelschmitz J, Alatrach A, Halabi A. Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment. Eur J Drug Metab Pharmacokinet. 2019 Oct;44(5):619-628. doi: 10.1007/s13318-019-00547-x. PubMed 30825073 ↗

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Sep 2014, 5 months.

Of 20 phase 1 interventional studies under Diabetic Nephropathies, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2021
First posted
May 11, 2021
StartActual
Mar 25, 2014
Primary completionActual
Sep 16, 2014
CompletionActual
Dec 8, 2014
Last update
Jul 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04881994
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
May 11, 2021
Start date
Mar 25, 2014
Primary completion
Sep 16, 2014
Completion
Dec 8, 2014
Last update
Jul 16, 2021

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion